Announcements Trials
Browse Landscape

Phase

Phase 2 38Phase 1/2 7Phase 1 5Phase 3 3Phase NA 2Phase 2/3 2Phase EARLY_PHASE1 1

Status

Recruiting 4Not yet recruiting 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

fludarabine 17Cyclophosphamide 16Positron Emission Tomography Computed Tomography 4Oncolytic Virotherapy 4Metformin 468Ga-pentixafor 4lenvatinib 3Radiosurgery 3Pemetrexed 3Paclitaxel 3Melphalan 3Immunotherapy, Adoptive 3Gemcitabine 3Cholestanetriol 26-Monooxygenase 3Carboplatin 3toripalimab 2sintilimab 2pembrolizumab 2gallium Ga 68 dotatate 2gallium 68 PSMA-11 2fludarabine phosphate 2alpha-Synuclein 2Progesterone 2Nivolumab 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Influenza Vaccines 2Fluorodeoxyglucose F18 2Ethiodized Oil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Unknown × Immune Checkpoint Inhibitors × Clear all
NCT03943472 2021-08-31

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Hrain Biotechnology Co., Ltd.

Phase EARLY_PHASE1 Unknown
10 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡